Patients using GLP-1 drugs had no difference in the odds of postoperative aspiration pneumonia versus non-users. Preoperative ...

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

GLP-1 receptor agonists show promise in treating alcohol addiction by modulating reward pathways and reducing cravings, offering a novel therapeutic approach.

Oxford Medical Products today announces additional three-month clinical trial results for Sirona, a weight-loss treatment targeting people who are overweight or have class I obesity (BMI 25-35) and ...

The finding that GLP-1 receptor agonists may be associated with a modest reduction in incident depression compared to DPP-4 inhibitors suggests that these agents could offer dual benefits ...